Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Psychosis and Antipsychotic Drugs: Overview

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.

The American journal of psychiatry·2016

Same author

Calming the Agitated Demented Patient.

The primary care companion for CNS disorders·2015

Same author

Posttraumatic stress disorder and dementia.

The primary care companion for CNS disorders·2015

Same author

All purulence is local - epidemiology and management of skin and soft tissue infections in three urban emergency departments.

BMC emergency medicine·2013

Same author

Crying wolf.

The primary care companion for CNS disorders·2012

Same author

Old age and loneliness.

The primary care companion for CNS disorders·2011

Search research articles

Related Experiment Video

Updated: Jul 1, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Using risperidone for Alzheimer's dementia-associated psychosis.

Karleen M McNeal¹, Renee P Meyer, Karen Lukacs

¹Alzheimer's Research and Clinical Programs, VA Medical Center and Medical University of South Carolina, Geriatrics and Extended Care, Charleston, SC, 29406-6076, USA.

Expert Opinion on Pharmacotherapy

|September 10, 2008

Summary

Risperidone is a common choice for Alzheimer's dementia (AD) psychosis, despite safety concerns. It may offer behavioral benefits for AD patients with severe agitation and aggression.

Related Experiment Videos

Last Updated: Jul 1, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Area of Science:

Geriatric Psychiatry
Neuroscience
Pharmacology

Background:

Alzheimer's dementia (AD) affects 6-8% of individuals over 65, rising to 30% in those over 85.
Psychosis occurs in 30-50% of AD patients, necessitating careful psychotropic agent use.
Safe and effective management of psychosis in AD is a significant clinical challenge.

Purpose of the Study:

To review the risks and benefits of using risperidone for psychosis associated with Alzheimer's dementia.
To evaluate the clinical efficacy and safety profile of risperidone in this patient population.

Main Methods:

Comprehensive literature review.
Analysis of clinical experience with risperidone in AD patients.
Discussion of efficacy, safety, and regulatory aspects.

Main Results:

Risperidone is frequently prescribed for AD-associated psychosis.
Potential for greater behavioral benefit in patients with severe agitation and aggression.
Safety concerns remain a consideration in treatment decisions.

Conclusions:

Risperidone continues to be a widely used option for managing psychosis in Alzheimer's dementia.
Careful patient selection may optimize therapeutic outcomes.
Balancing efficacy and safety is crucial for risperidone treatment in AD.